Hypertension and nephrology - 2024;28(1)

Hypertension and nephrology

FEBRUARY 28, 2024

[Nationwide comprehensive health protection screening program in Hungary (2010–2020–2030 – MÁESZ) analysis of blood pressure and metabolic status]

BARNA István, DAIKI Tenno, HALMY Eszter, KÉKES Ede, DANKOVICS Gergely

[The “Comprehensive Health Protection Screening Program of Hungary 2010-2020-2030” (MÁESZ) (http://www.egeszsegprogram.eu) is the only complex screening program in Hungary, in which we aimed to map the health status of our country. Between 2010 and 2021, the screening program carried out in the truck was present in 2,406 locations nationwide and performed more than nine million screening tests for more than 280,000 citizens.]

HUN 2024;28(1)

Hypertension and nephrology

FEBRUARY 28, 2024

[Investigation of lipid abnormalities in adult patients with hypertension using data mining method]

KOVÁCS Beáta, NÉMETH Ákos, DARÓCZY Bálint, KARÁNYI Zsolt, MARODA László, DIÓSZEGI Ágnes, PÁLL Dénes, HARANGI Mariann

[Hypertension and hyperlipidemia frequently coexist, and their interaction amplifies overall atherosclerotic cardiovascular disease risk. We aimed to investigate lipid abnormalities and their associations with body mass index (BMI) in a large adult hypertensive patient population with the help of data mining.]

HUN 2024;28(1)

Hypertension and nephrology

FEBRUARY 28, 2024

[Changes/new developments in pediatric nephrology I. – Vesicoureteral reflux (VUR)]

MÁTTYUS István

[In the case of vesicoureteral reflux (VUR), the abnormal backflow of urine from the bladder to the kidneys increases the risk of pyelonephritis and, in severe cases, causes kidney damage.]

HUN 2024;28(1)

Hypertension and nephrology

FEBRUARY 28, 2024

[Novelties and guidelines in cardiology, which can affect patients with chronic kidney failure]

SCHNEIDER Károly

[In cardiological guidelines, many strategic drugs (ACE-inhibitor/ARB, ARNi, beta-blocker, MRA, SGLT2-inhibitor) have made their way into recommendations with 1A level evidence for the prevention and treatment of cardiovascular diseases, depending on the type and severity of cardiovascular involvement and the co-incidence of other various comorbidities in heart conditions. In this summary we are going to elaborate on the fundamental
characteristics of classes of medications with different mechanism of actions,
cardiological evidences for their applications, their effects on patients with chronic renal diseases –, including those with end-stage renal diseases-, focusing mostly on their common cardio- and renoprotective attributes and the cardiological guidelines and the recommendations for patients with chronic renal failure, without attempting to be comprehensive.]

HUN 2024;28(1)

Hypertension and nephrology

FEBRUARY 28, 2024

[Patients with diabetes, renal failure and perimenopausal hypertension]

ÁBRAHÁM György

[The determinants of cardiovascular (CV) morbidity and mortality is sympathetic overweight, which is the main risk factor for CVD. factors - hypertension (HT), diabetes mellitus (T2DM), renal function deterioration (CKD), dyslipidaemia and, in women, the perimenopausal status - significantly potentiates the adverse effects of diabetes, dyslipidemia, diabetes mellitus.]

HUN 2024;28(1)

Hypertension and nephrology

FEBRUARY 28, 2024

[Important effects of renin-angiotensin system and angiotensin receptor blockers. Focus on valsartan]

FARSANG Csaba

[Blockade of AT1-receptors causes arteriolar vasodilation leading to the decrease the total peripheral resistance (TPR), the aldosterone secretion, and the sodium reabsorption in renal tubuli with reduction of the intraglomerular pressure.]

HUN 2024;28(1)

Hypertension and nephrology

FEBRUARY 28, 2024

[Quiz]

[ ]

HUN 2024;28(1)